-
ACS Chemical Neuroscience Feb 2023The arsenal of drugs for psychiatry has been difficult to renew for several decades. Many failures in therapeutic trials can be explained by poorly evaluated...
The arsenal of drugs for psychiatry has been difficult to renew for several decades. Many failures in therapeutic trials can be explained by poorly evaluated pharmacological properties, in terms of brain passage, target binding, and functional modulation. Positron emission tomography can provide pharmacokinetic and pharmacodynamic data that will help to better select candidate molecules for larger-scale clinical trials.
Topics: Positron-Emission Tomography; Brain; Psychiatry
PubMed: 36726331
DOI: 10.1021/acschemneuro.3c00036 -
PET Clinics Apr 2024During the last 2 decades, f-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG PET/CT) has transformed the clinical head and neck cancer... (Review)
Review
During the last 2 decades, f-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG PET/CT) has transformed the clinical head and neck cancer imaging for patient management and predicting survival outcomes. It is now widely used for staging, radiotherapy planning, posttherapy assessment, and for detecting recurrence in head and neck cancers and is widely included in NCCN and other evidence based clinical practice guidelines. Future Directions would include evaluating the potential value of FAPI PET/CT for head and neck cancers, opportunity to use volumetric and tumor heterogeneity parameters and deploying AI in diagnostic and therapeutic assessments.
Topics: Humans; Positron Emission Tomography Computed Tomography; Head and Neck Neoplasms; Positron-Emission Tomography; Fluorodeoxyglucose F18
PubMed: 38290968
DOI: 10.1016/j.cpet.2023.12.013 -
The British Journal of Radiology Dec 2011In an era in which it is possible to deliver radiation with high precision, there is a heightened need for enhanced imaging capabilities to improve tumour localisation... (Review)
Review
In an era in which it is possible to deliver radiation with high precision, there is a heightened need for enhanced imaging capabilities to improve tumour localisation for diagnostic, planning and delivery purposes. This is necessary to increase the accuracy and overall efficacy of all types of external beam radiotherapy (RT), including particle therapies. Positron emission tomography (PET) has the potential to fulfil this need by imaging fundamental aspects of tumour biology. The key areas in which PET may support the RT process include improving disease diagnosis and staging; assisting tumour volume delineation; defining tumour phenotype or biological tumour volume; assessment of treatment response; and in-beam monitoring of radiation dosimetry. The role of PET and its current developmental status in these key areas are overviewed in this review, highlighting the advantages and drawbacks.
Topics: Fluorodeoxyglucose F18; Forecasting; Humans; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tumor Burden
PubMed: 21427180
DOI: 10.1259/bjr/21263014 -
Neurologic Clinics Feb 2009This short review focuses on practical, present day, clinical application of FDG PET, a technology available to practicing neurologists for managing their patients.... (Review)
Review
This short review focuses on practical, present day, clinical application of FDG PET, a technology available to practicing neurologists for managing their patients. Indications in the disease states of dementia, neuro-oncology, epilepsy, parkinsonism, and other less common settings are reviewed. Many third-party payers currently make reimbursements based on these indications. By measuring an aspect of brain function, PET provides information that often is unobtainable from other sources, thus facilitating more rationale and cost-effective management, which can only benefit the patient, the referring physician, and the health care system as a whole.
Topics: Brain Diseases; Humans; Neurology; Positron-Emission Tomography
PubMed: 19055975
DOI: 10.1016/j.ncl.2008.09.004 -
Haematologica Jul 2010
Review
Topics: Disease Management; Hodgkin Disease; Humans; Positron-Emission Tomography; Prognosis
PubMed: 20595100
DOI: 10.3324/haematol.2010.024885 -
Seminars in Nuclear Medicine Jan 2013Although clinical positron emission tomography (PET)/computed tomography (CT) applications were obvious and have completely replaced PET in oncology, clinical... (Review)
Review
Although clinical positron emission tomography (PET)/computed tomography (CT) applications were obvious and have completely replaced PET in oncology, clinical applications of PET/magnetic resonance (MR) are currently not clearly defined. This is due to the lack of clinical data, which is mainly because PET/MR technology is not clinically mature at this point. Open issues are technical and concern ease of obtaining PET attenuation correction maps, dealing with, for example, MR surface coil metal in the PET field-of-view and appropriate workflows leading to a cost-effective examination. All issues can be circumvented by using a shuttle-connected PET/CT-MR system, but the penalty is that simultaneous PET and MR imaging are not possible and potential motion between examinations may occur. Clinically, some systems installed worldwide start to have a reasonable bulk of clinical data. Preliminary results suggest that in oncology, PET/MR may have advantages over PET/CT in head and neck imaging. In liver imaging, more PET-positive lesions are seen on MR than on CT, but that does not mean that PET/MR is superior to PET/CT. Possibly in some settings where a contrast-enhanced PET/CT is needed to be diagnostic, PET/MR can be done without contrast media. Although PET/CT has virtually no role in brain imaging, this may be an important domain for PET/MR, particularly in dementia imaging. The role of PET/MR in the heart is as yet undefined, and much research will have to be done to elucidate this role. At this point, it is also not clear where the simultaneity afforded by a fully integrated PET/MR is really needed. Sequential data acquisition even on separate systems and consecutive software image fusion may well be appropriate. With the increasing installed base of systems, clinical data will be forthcoming and define more clearly where there is clinical value in PET/MR at an affordable price.
Topics: Cardiology; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasms; Neurology; Positron-Emission Tomography
PubMed: 23178084
DOI: 10.1053/j.semnuclmed.2012.08.005 -
Clinical Pharmacology and Therapeutics Aug 2014Drug disposition is highly regulated by membrane transporters. Some transporter-mediated drug-drug interactions (DDIs) may not manifest themselves in changes in systemic... (Review)
Review
Drug disposition is highly regulated by membrane transporters. Some transporter-mediated drug-drug interactions (DDIs) may not manifest themselves in changes in systemic exposure but rather in changes in tissue exposure of drugs. To better assess the impact of transporter-mediated DDIs in tissues, positron emission tomography (PET)-a noninvasive imaging method--plays an increasingly important role. In this article, we provide examples of how PET can be used to assess transporter-mediated DDIs in different organs.
Topics: Animals; Drug Interactions; Humans; Membrane Transport Proteins; Pharmaceutical Preparations; Positron-Emission Tomography; Tissue Distribution
PubMed: 24682030
DOI: 10.1038/clpt.2014.70 -
The Journal of Thoracic and... Jan 2023
Commentary: Lest we biopsy: Positron emission tomography-computed tomography as a tool to achieve a "greater good" in the diagnosis and management of the resectable anterior mediastinal mass.
Topics: Humans; Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18; Positron-Emission Tomography; Biopsy; Neoplasm Staging; Lung Neoplasms; Radiopharmaceuticals
PubMed: 35525804
DOI: 10.1016/j.jtcvs.2022.02.057 -
Radiotherapy and Oncology : Journal of... Sep 2010Positron emission tomography can be used in radiation oncology for the delineation of target volumes in the treatment planning stage. Numerous publications deal with... (Review)
Review
Positron emission tomography can be used in radiation oncology for the delineation of target volumes in the treatment planning stage. Numerous publications deal with this topic and the scientific community has investigated many methodologies, ranging from simple uptake thresholding to very elaborate probabilistic models. Nevertheless, no consensus seems to emerge. This paper reviews delineation techniques that are popular in the literature. Special attention is paid to threshold-based techniques and the caveats of this methodology are pointed out by formal analysis. Next, a simple model of positron emission tomography is suggested in order to shed some light on the difficulties of target delineation and how they might be eventually overcome. Validation aspects are considered as well. Finally, a few recommendations are gathered in the conclusion.
Topics: Humans; Neoplasms; Positron-Emission Tomography
PubMed: 20708286
DOI: 10.1016/j.radonc.2010.07.003 -
Expert Review of Anticancer Therapy Apr 2006This review continues from a previous review on this topic, which was published in the December issue. In that review, the role of positron emission tomography in lung... (Review)
Review
This review continues from a previous review on this topic, which was published in the December issue. In that review, the role of positron emission tomography in lung cancer, lymphoma, breast cancer, head and neck cancer, gastroesophageal cancer, colorectal cancer, malignant melanoma, bone tumors and ovarian cancer was discussed. In this review, the role of positron emission tomography in other malignancies, such as gynecological malignancies other than ovary, pancreatic cancer, hepatocellular cancer, gastrointestinal tumors, urological malignancies, neuroendocrine tumors, adrenocortical tumors, soft-tissue sarcomas, pituitary and brain tumors, is discussed.
Topics: Humans; Medical Oncology; Neoplasms; Positron-Emission Tomography
PubMed: 16613549
DOI: 10.1586/14737140.6.4.625